Acquisition - Alcon will acquire STAAR Surgical for \$28 per share in cash, representing a ~59% premium to STAAR's 90-day volume-weighted average price[15] - The acquisition represents a total equity value of approximately \$1.5 billion and is expected to be funded through short- and long-term credit facilities[15] - The acquisition is expected to be accretive to core diluted EPS in year two[15] Financial Highlights (Q2 2025) - Net sales reached \$2.6 billion, a 4% increase year-over-year on a reported basis and a 3% increase in constant currency[21] - Core operating margin was 19.1%, a decrease of 70 basis points[21] - Core diluted EPS was \$0.76, compared to \$0.74 in Q2 2024[20] Financial Highlights (1H 2025) - Net sales reached \$5.0 billion[26] - Free cash flow was \$681 million[20] Product Mix (1H 2025 Sales) - Vision Care accounted for 45% (\$2.2 billion) of sales, while Surgical accounted for 55% (\$2.8 billion)[27] - Within Vision Care, contact lenses represented 62% of sales[27] - Within Surgical, consumables represented 53% of sales[27] FY 2025 Outlook (Updated) - Net sales are projected to be between \$10.3 to \$10.4 billion[64] - Core operating margin is expected to be between 19.5% to 20.5%[64] - Core diluted EPS is maintained at \$3.05 to \$3.15[64]

Optejet Technology and Design - Optejet采用专利技术，以温和的雾状形式将药物直接输送到所需部位[9] - Optejet的设计旨在解决易用性和剂量精确性的问题，在提高耐受性和减少副作用的同时，确保疗效[10] - Optejet的喷嘴有109个激光钻孔[10][15] - Optejet的用户填充药筒可以由用户使用普通滴眼液瓶中的药物填充[17] Regulatory and Intellectual Property - Optejet是FDA注册的I类医疗器械[1][14] - Optejet产品被FDA认为是“眼科计量喷雾剂”，不能用滴眼液替代[29] - 该公司拥有广泛的知识产权组合，有效期至2041年[27] - 公司已获得18项美国专利，另有8项正在申请中；已获得89项国外专利，另有33项正在申请中[29] Compliance and Digital Integration - Optejet能够自动跟踪使用情况[21] - Optejet配备内置的Optecare技术，用于跟踪和交流患者依从性数据[24] - 在临床研究中，前28名受试者的每日治疗依从性远高于预测值[24] Partnerships - Senju Pharmaceuticals获得了Optejet产品系列在亚洲的许可[33] - Artic Vision获得了Senju授予的Optejet产品系列在大中华区和韩国的部分转许可[33]